Pharmacyclics, Inc. (NASDAQ:PCYC)
CAPS Rating:
A pharmaceutical company focused on the development of products that improve existing therapeutic approaches to cancer and other diseases.
A pharmaceutical company focused on the development of products that improve existing therapeutic approaches to cancer and other diseases.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
Recs
After the Dendreon panel recommendation, Pharmacyclics made a filing with the FDA that among other things seeks a review of Xcytrin by an outside panel of experts. This coupled with lung cancer advocacy group involvement increases the chances of a favorable outcome regarding FDA approval.